AFFiRiS AG Revenue and Competitors

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients. WE FOCUS ON UNMET MEDICAL NEEDS IN CHRONIC DISEASES Currently available treatments for many neurodegenerative diseases aim to manage symptoms, and do not stop disease progression. As a result, neurodegenerative diseases often lead to a reduced quality of life. Better treatments for these diseases are needed to give patients healthier, happier, and longer lives. We aim to develop therapeutic and preventative treatments that address the root causes of neurodegenerative diseases: an ethos inspired by the impact of vaccines on health and society worldwide. OUR APPROACH Our novel approach, Specific Active ImmunoTherapy (SAIT), stimulates the body's own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT was developed using our AFFITOME technology, which allows for optimization of immune responses against pathogenic forms of proteins, and it may permit targeting of multiple pathogenic proteins in one disease setting. SAIT is designed to induce a long-lasting immune response, which we anticipate will translate into effective quarterly/twice-yearly dosing. OUR PIPELINE We have a broad portfolio of immunotherapy candidates, which are currently in clinical trials or preclinical development for chronic diseases, including Parkinson's Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease. OUR TEAM We are a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. Our exciting work spans early discovery, preclinical advancement of SAIT and monoclonal antibody drug candidates, and translation of science into clinical development. Please follow us on LinkedIn and visit www.affiris.com.